Status | Study |
Not yet recruiting |
Study Name: A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN Condition: C3 Glomerulonephritis Dense Deposit Disease Date: 2017-04-12 Interventions: Drug: ACH-0144471 ACH-0144471 will be administered to all patients enrolled in the study. |
Recruiting |
Study Name: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Condition: IgAN Lupus Nephritis MN Date: 2016-02-10 Interventions: Biological: OMS721 Biological: |
Withdrawn |
Study Name: TP10 Use in Patients With C3 Glomerulopathy (C3G) Condition: Dense Deposit Disease Date: 2014-11-05 Interventions: Drug: TP10 All patients will be enrolled through the University of Iowa. This study will follow a patien |
Terminated |
Study Name: Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease Condition: Dense Deposit Disease Membranoproliferati Date: 2013-01-29 Interventions: Drug: CDX-1135 Other Names: TP10 sCR1 |
Withdrawn |
Study Name: Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Condition: Dense Deposit Disease Membranoproliferative Glomerulonephritis Date: 2010-10-13 Interventions: Drug: Eculizumab 900 mg IV once a week x 4 weeks, 1200 mg |
Withdrawn |
Study Name: Sulodexide Treatment in Patients With Dense Deposit Disease Condition: Dense Deposit Disease Date: 2007-12-20 Interventions: Drug: Sulodexide 200 mg per day in an oral gelcap form |